Genetic toxicities of human teratogens

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 396, Issue 1-2, 1997, Pages 9-43

  Bishop, Jack B ^a   Witt, Kristine L ^b   Sloane, Richard A ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMINOPTERIN; ANDROGEN; ANTINEOPLASTIC AGENT; BUSULFAN; CIGARETTE SMOKE; COCAINE; COUMARIN ANTICOAGULANT; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DETORUBICIN; DIETHYLSTILBESTROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDOMETACIN; LITHIUM; MEPHENYTOIN; MERCAPTOPURINE; METHOTREXATE; METHYLENE BLUE; MUTAGENIC AGENT; PENICILLAMINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RETINOID; TERATOGENIC AGENT; TETRACYCLINE DERIVATIVE; THIAMAZOLE; UNINDEXED DRUG;

BIRTH DEFECT; CHROMOSOME ABERRATION; CONGENITAL MALFORMATION; DRUG MECHANISM; GENE MUTATION; GENOTOXICITY; HUMAN; MOUSE; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; TERATOGENESIS;

EID: 17144437268     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(97)00173-5     Document Type: Article

References (303)

1. Dubrova Y.E., Nesterov V.N., Krouchinsky N.G., Ostapenko V.A., Neumann R., Neil D.L., Jeffreys A.J. Human minisatellite mutation rate after the Chernobyl accident. Nature. 380:1996;683-686.
2. J.C. Rutledge, Developmental toxicity induced during early stages of mammalian embryogenesis, Mutation Res., this issue.
3. T.H. Shepard, Catalog of Teratogenic Agents, John Hopkins University Press, Baltimore, 1995.
4. J.L. Schardein, Chemically Induced Birth Defects, Marcel Dekker, New York, 1993.
5. J.G. Wilson, Embryotoxicity of drugs in man, in: J.G. Wilson, F.C. Fraser (Eds.), Handbook of Teratology, Plenum Press, New York, 1977, pp. 309-355.
6. Brent R.L. Editor's note. Teratology. 17:1978;183.
7. Z. Stein, J. Kline, M. Kharrazi, What is a teratogen? Epidemiologic criteria, in: H. Kalter (Ed.), Issues and Reviews in Teratology, Plenum Press, New York, 1984, pp. 23-66.
8. Hemminki K., Vineis P. Extrapolation of the evidence on teratogenicity of chemicals between humans and experimental animals: Chemicals other than drugs. Teratog. Carcinog. Mutagen. 5:1985;251-318.
9. T.H. Shepard, Catalog of Teratogenic Agents, John Hopkins University Press, Baltimore, 1973-1992.
10. Mole R.H. Irradiation of the embryo and fetus. Br. J. Radiol. 60:1987;17-31.
11. J.M. Friedman, J.E. Polifka, Teratogenic Effects of Drugs: A Resource for Clinicians (TERIS), The John Hopkins University Press, Baltimore, 1994.
12. R. Rieger, A. Michaelis, M.M. Green, Glossary of Genetics: Classical and Molecular, Springer-Verlag, New York, 1991.
13. Roy M., Sengupta S., Bhattacharyya N.P., Dey S.K., Bhattacharjee S.B. Response of MTX-resistant V79 cells to some DNA-damaging agents. Mutation Res. 285:1993;199-207.
14. Bridges B.A., Greaves M., Polani P.E., Wald N. Do treatments available for psoriasis patients carry a genetic or carcinogenic risk? Mutation Res. 86:1981;279-304.
15. Benedict W.F., Baker M.S., Haroun L., Choi E., Ames B.N. Mutagenicity of cancer chemotherapeutic agents in the Salmonella/microsome test. Cancer Res. 37:1977;2209-2213.
16. Matheson D., Brusick D., Carrano R. Comparison of the relative mutagenic activity for eight antineoplastic drugs in the Ames Salmonella/microsome and TK± mouse lymphoma assays. Drug Chem. Toxicol. 1:1978;277-304.
17. Dickins M., Wright K., Phillips M., Todd N. Toxicity and mutagenicity of 6 anti-cancer drugs in Chinese hamster V79 cells co-cultured with rat hepatocytes. Mutation Res. 157:1985;189-197.
18. A.C. Stevenson, Effects of twelve folate analogues on human lymphocytes in vitro, in: H.J. Evans, D.C. Lloyd (Eds.), Mutagen-induced Chromosome Damage in Man, University Press, Edinburgh, 1978, pp. 227-238.
19. Kasahara Y., Nakai Y., Miura D., Yagi K., Hirabayashi K., Makita T. Mechanism of induction of micronuclei and chromosome aberrations in mouse bone marrow by multiple treatments of methotrexate. Mutation Res. 280:1992;117-128.
20. Higashikuni N., Sutou S. An optimal, generalized sampling time of 30±6 h after double dosing in the mouse peripheral blood micronucleus test. Mutagenesis. 10:1995;313-319.
21. Maier P., Schmid W. Ten model mutagens evaluated by the micronucleus test. Mutation Res. 40:1976;325-327.
22. Yamamoto K.I., Kikuchi Y. Studies on micronuclei time response and on the effects of multiple treatments of mutagens on induction of micronuclei. Mutation Res. 90:1981;163-173.
23. Kasahara Y., Wakata A., Nakai Y., Yuno K., Miura D., Yagi K., Hirabayashi K., Makita T. The micronucleus test using peripheral blood reticulocytes from methotrexate-treated mice. Mutation Res. 278:1992;145-151.
24. Bruman V., Horvat D. Work environment influence on cytostatics-induced genotoxicity in oncologic nurses. Am. J. Ind. Med. 30:1996;67-71.
25. Lindskov R., Wulf H.C., Wantzin G.L., Niebuhr E. Sister chromatid exchange in patients treated with methotrexate for psoriasis. J. Invest. Dermatol. 82:1984;458-459.
26. Raffetto G., Parodi S., Faggin P., Maconi A. Relationship between cytotoxicity and induction of sister-chromatid exchanges in mouse foetal cells exposed to several doses of carcinogenic and non-carcinogenic chemicals. Mutation Res. 63:1979;335-343.
27. Propping P., Rohrborn G., Buselmaier W. Comparative investigations on the chemical induction of point mutations and dominant lethal mutations in mice. Mol. Gen. Genet. 117:1972;197-209.
28. Hansmann I. Chromosome aberrations in metaphse II oocytes: stage sensitivity in mouse oogenesis to amethopterin and cyclophosphamide. Mutation Res. 22:1974;174-191.
29. Slijepcevic P., Natarajan A.T. Fragile site at Xq21 in Chinese hamster and its implications for the in vitro chromosomal aberration test. Mutagenesis. 10:1995;353-355.
30. Reidy J.A., Zhou X., Chen A.T. Folic acid and chromosome breakage I. Implications for genotoxicity studies. Mutation Res. 122:1983;217-221.
31. MacGregor J.T., Schlegel R., Wehr C.M., Alperin P., Ames B.N. Cytogenetic damage induced by folate deficiency in mice is enhanced by caffeine. Proc. Natl. Acad. Sci. USA. 87:1990;9962-9965.
32. Witt K.L., Bishop J.B. Mutagenicity of anticancer drugs in mammalian germ cells. Mutation Res. 355:1996;209-234.
33. Bishop J.B., Wassom J.S. Toxicological review of busulfan (Myleran). Mutation Res. 168:1986;15-45.
34. Benfatto G. Chronic leukemic myelosis in pregnancy. Clin. Ginecol. 1:1959;131-137.
35. Diamond I., Anderson M.M., McCradie S.R. Transplancental transmission of busulfan in a mother with leukemia. Pediatrics. 25:1960;85-90.
36. Bhisey A.N., Advani S.H., Khare A.G. Cytogenetic anomalies in a child born to a mother receiving busulfan for chronic myeloid leukemia. Indian J. Cancer. 19:1982;272-276.
37. Seino Y., Nagao M., Yahagi T., Hoshi A., Kawachi T., Sugimura T. Mutagenicity of several classes of antitumor agents to Salmonella typhimurium TA98, TA100, and TA92. Cancer Res. 38(7):1978;2148-2156.
38. Foureman P., Mason J.M., Valencia R., Zimmering S. Chemical mutagenesis testing in Drosophila. X. Results of 70 coded compounds tested for the National Toxicology Program Environ. Mol. Mutagen. 23:1994;208-227.
39. Charles D., Leonard A. Mutagenicity tests with phenylbutazone in mammals. Toxicol. Lett. 2:1978;225-230.
40. Ehling U.H., Malling H.V. 1,4-di(methanesulfonoxy)butane (Myleran) as a mutagenic agent in mice. Genetics. 60:1968;174-175.
41. Generoso W.M., Huff S.W., Stout S.K. Chemically induced dominant-lethal mutations and cell killing in mouse oocytes in the advanced stages of follicular development. Mutation Res. 11:1971;411-420.
42. Ehling U.H., Neuhauser-Klaus A. Induction of specific-locus and dominant lethal mutations in male mice by busulfan. Mutation Res. 249:1991;285-292.
43. Bollag W. Cytostatics in pregnancy. Schweiz Med. Wochenschr. 84:1954;393-395.
44. Heller R.H., Jones H.W. Production of ovarian dysgenesis in the rat and human by busulfan. Am. J. Obstet. Gynecol. 89:1964;414-420.
45. Hemsworth B.N., Jackson H. Effect of 'busulphan' on the fetal gonad. Nature. 195:1962;816-817.
46. IARC Tobacco smoke. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. 7:1987;360-362.
47. Zenzes M.T., Wang P., Casper R.F. Cigarette smoking may affect meiotic maturation of human oocytes. Human Reprod. 10:1995;3213-3217.
48. Au W.W., Walker D.M., Ward J.B., Whorton E., Legator M.S., Singh V. Factors contributing to chromosome damage in lymphocytes of cigarette smokers. Mutation Res. 260:1991;137-144.
49. Holmen A., Karlsson A., Bratt I., Hogstedt B. Increased frequencies of micronuclei in T8 lymphocytes of smokers. Mutation Res. 334:1995;205-208.
50. Stich H.F., Rosin M.P. Quantitating the synergistic effect of smoking and alcohol consumption with the micronucleus test on human buccal mucosa cells. Int. J. Cancer. 31:1983;305-308.
51. Burgaz S., Iscan A., Buyukbingol Z.K., Bozkurt A., Karakaya A.E. Evaluation of micronuclei in exfoliated urothelial cells and urinary thiether excretion of smokers. Mutation Res. 335:1995;163-169.
52. Balansky R.M., Blagoeva P.M. Tobacco smoke-induced clastogenicity in mouse fetuses and in newborn mice. Mutation Res. 223:1989;1-6.
53. Livingston G.K., Fineman R.M. Correlation of human lymphocyte SCE frequency with smoking history. Mutation Res. 119:1983;59-64.
54. Esser K.J., Kotlarek F., Habedank M., Muhler U., Muhler E. Chromosomal investigations in epileptic children during long-term therapy with phenytoin or primidone. Hum. Genet. 56:1981;345-348.
55. Lundberg M.S., Livingston G.K. Sister-chromatid exchange frequency in lymphocytes of smoking and nonsmoking mothers and their newborn infants. Mutation Res. 121:1983;241-246.
56. Spielmann H., Jacob-Muller U. Investigations on cyclophosphamide treatment during the preimplantation period. 2. In vitro studies on the effects of cyclphosphamide and its metabolites 4-OH-cyclophosphamide, phosphoramide mustard, and acrolein on blastulation of four-cell and eight-cell mouse embryos and on their subsequent development during implantation Teratology. 23:1981;7-31.
57. Hales B.F. Comparison of the mutagenicity and teratogenicity of cyclophosphamide and its active metabolites, 4-hydroxycyclophos-phamide, phosphoramide mustard and acrolein. Cancer Res. 42:1982;3016-3021.
58. Mirkes P.E., Ricks J.L., Pascoe-Mason J.M. Cell cycle analysis in the cardiac and neuroepithelial tissues of day 10 rat embryos and the effects of phosphoramide mustard, the major teratogenic metabolite of cyclophosphamide. Teratology. 39:1989;115-120.
59. Anderson D., Bishop J.B., Garner R.C., Garner P., Ostrosky-Wegman P., Selby P.B. Cyclophosphamide: Review of its mutagenicity for an assessment of potential germ cell risks. Mutation Res. 330:1995;115-181.
60. Jenkinson P.C., Anderson D. Malformed foetuses and karyotype abnormalities in the offspring of cyclophosphamide and allyl alcohol-treated male rats. Mutation Res. 229:1990;173-184.
61. Jenkinson P.C., Anderson D., Gangolli S.D. Increased incidence of abnormal foetuses in the offspring of cyclophosphamide-treated male mice. Mutation Res. 188:1987;57-62.
62. Ferguson L.R., Hill C.L., Morecombe P. Induction of resistance to 6-thioguanine and cytarabine by a range of anticancer drugs in Chinese hamster AA8 cells. Eur. J. Cancer. 23A(4)(5):1992;736-742.
63. Spencer D.L., Hines K.C., Caspary W.J. An in situ protocol for measuring the expression of chemically-induced mutations in mammalian cells. Mutation Res. 312:1994;85-97.
64. Bean C.L., Armstrong M.J., Galloway S.M. Effect of sampling time on chromosome aberration yield for 7 chemicals in Chinese hamster ovary cells. Mutation Res. 265:1992;31-44.
65. Beaula-Helen K.D., Subramanyam S. Genotoxic evaluation of Ara-C by multiple parameters. Mutation Res. 263:1991;185-196.
66. Ren L., Zhang H., Yang H., Zhang Z. A sequential study on the use of the cytokinesis-block micronucleus method in mouse splenocytes. Mutation Res. 301:1993;223-227.
67. Hayashi M., Sofuni T., Ishidate M. Kinetics of micronucleus formation in relation to chromosomal aberrations in mouse bone marrow. Mutation Res. 127:1984;129-137.
68. Schleuning M., Clemm C. Chromosomal aberrations in a newborn whose mother received cytotoxic treatment during pregnancy. N. Engl. J. Med. 317:1987;1666-1667.
69. Ornaghi F., Giavini E. Induction of micronuclei in pre-implantation rat embryos in vivo. Mutation Res. 225:1989;71-74.
70. Cebula T.A. Genetic and physiological modulation of anthracycline-induced mutagenesis in Salmonella typhimurium. Environ. Mutagen. 8:1986;675-692.
71. Marzin D., Jasmin C., Maral R., Mathe G. Mutagenicity of eight anthracycline derivatives in five strains of Salmonella typhimurium. Eur. J. Cancer Clin. Oncol. 19:1983;641-647.
72. Gasiorowski K., Szyba K., Brokos B., Kozubek A. Antimutagenic activity of alkylresorcinols from cereal grains. Cancer Lett. 106:1996;109-115.
73. Helbig R., Speit G. The pattern of adriamycin-induced mutations in V-E5 Chinese hamster cells with chromosomal instability. Mutation Res. 348:1995;1-6.
74. Parkes D.J., Scott D. A quantitative comparison of cytogenetic effects of anti-tumor agents. Cytogenet. Cell Genet. 33:1982;27-34.
75. Szabova E. Comparison of the in vitro effect of adriblastina on induction of SCEs in V79 cells and human peripheral blood lymphocytes. Neoplasma. 43:1996;407-409.
76. Toppari J., Lahdetie J., Harkonen P., Eerola E., Parvinen M. Mutagen effects on rat seminiferous tubules in vitro: induction of meiotic micronuclei by adriamycin. Mutation Res. 171:1986;149-156.
77. Katoh M.A., Cain K.T., Hughes L.A., Foxworth L.B., Bishop J.B., Generoso W.M. Female specific dominant lethal effects in mice. Mutation Res. 230:1990;205-217.
78. Sulik K.K., Johnson M.C. Acute ethanol administration in an animal model results in craniofacial features characteristic of the fetal alcohol syndrome. Science. 214:1982;936-938.
79. Veghelyi P.V., Osztrovics M., Kardos G., Leisztner L., Szaszovszky E., Igali S., Imrei J. The fetal alcohol syndrome: symptoms and pathogenesis. Acta Paediat. Acad. Sci. Hung. 19:1978;171-189.
80. Jones K.L., Chambers C.C., Johnson K.A. The effect of disulfiram on the unborn baby. Teratoloty. 43(5):1991;438.
81. Vainio H., Waters M.D., Norppa H. Mutagenicity of selected organic solvents. Scand. J. Work Environ. Health. 11:1985;75-82.
82. McCann J., Choi E., Yamasaki E., Ames B.N. Detection of carcinogens as mutagens in the Salmonella/microsome test: Assay of 300 chemicals. Proc. Natl. Acad. Sci. USA. 72:1975;5135-5139.
83. Zeiger E., Anderson B., Haworth S., Lawlor T., Mortelmans K. Salmonella mutagenicity tests V. Environ. Mol. Mutagen. 19(suppl. 21):1992;2-141.
84. deFlora S., Camoirano A., Zanacci P., Bennicelli C. Mutagenicity testing with TA97 and TA102 of 30 DNA-damaging compounds, negative with other Salmonella strains. Mutation Res. 134:1984;159-165.
85. Loquet C., Toussaint G., LeTalaer J.Y. Studies on mutagenic constituents of apple brandy and various alcoholic beverages collected in Western France, a high incidence area of oesophageal cancer. Mutation Res. 88:1981;155-164.
86. Lotfi C.F., Brentani M.M., Bohm G.M. Assessment of the mutagenic potential of ethanol auto engine exhaust gases by the Salmonella typhimurium microsomal mutagenesis assay, using a direct exposure method. Environ Res. 52:1990;225-230.
87. F.M. Badr, R.S. Badr, R.L. Asker, F.H. Hussain, Evaluation of the mutagenic effects of ethyl alcohol by different techniques, in: M.M. Cross (Ed.), Alcohol Intoxication and Withdrawal, IIIa, Biological Aspects of Ethanol, Plenum Press, New York, 1977, pp. 25-46.
88. Brown N.M., Trizna Z., Pathak S. Clastogenic interactions between lobeline sulfate and ethyl alcohol: a cytogenetic study. Anticancer Res. 12:1992;1467-1469.
89. deRaat W.K., Davis P.B., Bakker G.L. Induction of sister-chromatid exchanges by alcohol and alcoholic beverages after activation by rat-liver homogenate. Mutation Res. 124:1983;85-90.
90. Jansson T. The frequency of sister chromatid exchanges in human lymphocytes treated with ethanol and acetaldehyde. Hereditas. 97:1982;301-303.
91. Takehisa S., Nanaya N. A comparison of Vicia-faba-root S10 and rat-liver S9 activation of ethanol, maleic hydrazide and cyclophosphamide as measured by sister-chromatid exchange induction in Chinese hamster ovary cells. Mutation Res. 124:1983;145-151.
92. Obe G., Anderson D. International Commission for Protection against Environmental Mutagens and Carcinogens. ICPEMC Working Paper No. 15/1. Genetic effects of ethanol. Mutation Res. 186:1987;177-200.
93. Obe G., Natarajan A.T., Meyers M., Den Hertog A. Induction of chromosomal aberrations in peripheral blood lymphocytes of human blood in vitro, and of SCEs in bone-marrow cells of mice in vivo by ethanol and its metabolite acetaldehyde. Mutation Res. 68:1979;291-294.
94. Pina-Calva A., Madrigal-Bujaidar E. SCE frequencies induced by ethanol, tequila and brandy in mouse bone marrow cells in vivo. Toxicol. Lett. 66:1993;1-5.
95. Baraona E., Guerra M., Lieber C.S. Cytogenetic damage of bone marrow cells produced by chronic alcohol consumption. Life Sci. 29:1981;1797-1802.
96. D.B. McGregor, S. De, S. Wickramaratne, Does ethanol cause chromosomal aberrations?, Second Int. Conf. Environ. Mutagen., 1977, 89.
97. Badr F.M., Badr R.S. Induction of dominant lethal mutation in male mice by ethyl alcohol. Nature. 253:1975;134-136.
98. Cole J., Green M.H. Absence of evidence for mutagenicity of alcoholic beverages: an analysis of hprt mutant frequencies in 153 normal humans. Mutagenesis. 10:1995;449-452.
99. Burke D.A., Wedd D.J., Herriott D., Bayliss M.K., Spalding D.J., Wilcox P. Evaluation of pyrazole and ethanol induced S9 fraction in bacterial mutagenicity testing. Mutagenesis. 9:1994;23-29.
100. Hu Y., Ingelman-Sundberg M., Lindros K.O. Induction mechanisms of cytochrome P450 2E1 in liver: interplay between ethanol treatment and starvation. Biochem. Pharmcol. 50:1995;155-161.
101. Glatt H., deBalle L., Oesch E. Ethanol- or acetone-pretreatment of mice strongly enhances the bacterial mutagenicity of dimethylnitrosamine in assays mediated by liver subcellular faction, but not in host-mediated assays. Carcinogenesis. 2:1981;1057-1061.
102. Wronska-Nofer T., Wisnieswask-Knypl J., Wysynska K. Cytochrome P450 mediated genotoxicity of triarylmethane dye in mice fed ethanol liquid diet. Int. J. Occup. Med. Environ. Health. 8:1995;367-375.
103. Runner M.N. Epigenetically regulated genomic expressions for shortened stature and cleft palate are regionally specific in the 11-day mouse embryo. J. Carniofac. Genet. Dev. Biol. Suppl. 2:1986;137-168.
104. Criswell H.E., Simson P.E., Duncan G.E., McCown T.J., Herbert J.S., Morrow A.L., Breese G.R. Molecular basis for regionally specific action of ethanol on gamma-animobutyric acidA receptors: generalization to other ligand-gated ion channels. J. Pharmacol. Exp. Ther. 267:1993;522-537.
105. Breese C.R., D'Costa A., Sonntag W.E. Effect of in utero ethanol exposure on the postnatal ontogeny of insulin-like growth factor-1, and type-1 and type-2 insulin-like growth factor receptors in the rat brain. Neuroscience. 63:1994;579-589.
106. De A., Boyadjieva N.I., Pastorcic M., Reddy B.V., Sarkar D.K. Cyclic AMP and ethanol interact to control apoptosis and differentiation in hypothalamic beta-endorphin neurons. J. Biol. Chem. 269:1994;26697-26705.
107. Freund G. Apoptosis and gene expression: perspectives on alcohol-induced brain damage. Alcohol. 11:1994;385-387.
108. Wilce P., Beckman A., Shanley B., Matsumoto I. Gene expression during ethanol withdrawal. Alcohol. 2:1994;97-102.
109. Reimers T.J., Sluss P.M. 6-Mercaptopurine treatment of pregnant mice: effects on second and third generations. Science. 201:1978;65-67.
110. Mosesso P., Palitti F. The genetic toxicology of 6-mercaptopurine. Mutation Res. 296:1993;279-294.
111. Amacher D.E., Pailler S.C., Turner G.N., Ray V.A., Salsburg D.S. Point mutations at the thymidine kinase locus in L5178Y mouse lymphoma cells 2. Test validation and interpretation. Mutation Res. 72:1980;447-474.
112. Sono A., Sakaguchi K. Induction of sister chromatid exchanges in Chinese hamster cells by antitumor agents and its relation to chromosome aberrations. Cell Struct. Funct. 3:1978;341-347.
113. Holden H.E., Ray V.A., Wahrenburg M.G., Zelenski J.D. Mutagenicity studies with 6-mercaptopurine I. Cytogenetic activity in vivo. Mutation Res. 20:1973;257-263.
114. Cozzi R., Palitti F., Fiore M., Mosesso P., Ricordy R., Tanzarella C. Induction of chromosomal damage both in vitro and in vivo by 6-mercaptopurine. INSERM/EEMS. 119:1983;229-232.
115. Generoso W.M., Preston R.J., Brewen J.G. 6-Mercaptopurine: an inducer of cytogenetic and dominant lethal effects in premeiotic and early meiotic germ cells of male mice. Mutation Res. 28:1975;437-447.
116. Russell L.B., Hunsicker P.R. Study of the base analog 6-mercaptopurine in the mouse specific-locus test. Mutation Res. 176:1987;47-52.
117. W.M. Generoso, K.T. Cain, S.W. Huff, D.G. Gosslee, Inducibility by chemical mutagens of hereditable translocations in male and female germ cells of mice, in: W.G. Flamm, M. Mehlman (Eds.), Advances in Modern Toxicology, Hemisphere, Washington, DC, 1978, pp. 109-129.
118. Stark A.A., Glass G.A. Role of copper and ceruloplasmin in oxidative mutagenesis induced by the glutathione-gamma-glutamyl transpeptidase system and by other thiols. Environ. Mol. Mutagen. 29:1997;63-72.
119. Stark A.A., Arad A., Siskindovich S., Pagano D.A., Zeiger E. Effect of pH on mutagenesis by thiols in Salmonella typhimurium TA102. Mutation Res. 224:1989;89-94.
120. Speit G., Haupter S. Cytogenetic effects of penicillamine. Mutation Res. 190:1987;197-203.
121. Glatt H., Utesch D., Herbst M., Oesch F. Mutagenicity experiments on L-cysteine and D-penicillamine using V79 cells as indicators and for metabolic activation. Mutation Res. 243:1990;187-193.
122. Motimaya A.M., Subramanya K.S., Curry P.T., Kitchin R.M. Evaluation of the genotoxic potential of selected anti-AIDS treatment drugs at clinical doses in vivo in mice. Toxicol. Lett. 70:1994;171-183.
123. Ahmed A.E., Nouraldeen A.M., Abdel-Rahman S.Z., Rajaraman S. Role of glutathione modulation in acrylonitrile-induced gastric DNA damage in rats. Arch. Toxicol. 70:1996;620-627.
124. Deleuran B., Kristensen M., Paludan K., Zachariae C., Larsen C.G., Zachariae E., Thestrup-Pedersen K. The effect of second-line antirheumatic drugs on interleukin-8 mRNA synthesis and protein secretion in human endothelial cells. Cytokine. 4:1992;403-409.
125. Fuchs O. Ferrochelatase gene expression in erythroid cells. Cas. Lek. Cesk. 131:1992;741-745.
126. Monestier M., E N.K., Losman M.J. D-penicillamine- and quinidine-induced antinuclear antibodies in A.SW (H-2s) mice: similarities with autoantibodies in spontaneous and heavy metal induced autoimmunity. Eur. J. Immunol. 24:1994;723-730.
127. Randall V.A. Role of 5 alpha-reductase in health and disease. Baillieres Clin. Endocrinol. Metab. 8:1994;405-431.
128. Yalcinkaya T.M., Siiteri P.K., Vigne J.L., Licht P., Pavgi S., G F.L., Glickman S.E. A mechanism for virilization of female spotted hyenas in utero. Science. 260:1993;1929-1931.
129. Denmeade S.R., Lin X.S., Isaacs J.T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate. 28:1996;251-265.
130. Isaacs J.T., Furuya Y., Berges R. The roll of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin. Cancer Biol. 5:1994;391-400.
131. Degawa M., Yamaya C., Hashimoto Y. Hepatic cytochrome P-450 isozymes(s) induced by dietary carcinogenic aromatic amines preferentially in female mice of DBA/2 and other strains. Carcinogenesis. 9:1988;567-571.
132. Fysh J.M., Andrews L.S., Nebert D.W. Androgen receptor-mediated genetic differences in 2-acetylaminofluorene and dimethylnitrosamine mutagenesis in vitro. Anticancer Res. 3:1983;305-310.
133. Richold M. The genotoxicity of trenbolone, a synthetic steroid. Arch. Toxicol. 61:1988;249-258.
134. Abel E.L. Paternal behavioral mutagenesis. Neurotoxicology. 10:1989;335-345.
135. Weaver D.R., Roca A.L., Reppert S.M. c-fos and jun-B mRNAs are transiently expressed in fetal rodent suprachiasmatic nucleus following dopaminergic stimulation. Brain Res. Dev. 85:1995;293-297.
136. Daunais J.B., McGinty J.F. The effects of D1 or D2 dopamine receptor blockade on zif/268 and preprodynorphin gene expression in rat forebrain following a short-term cocaine binge. Brain Res. Mol. 35:1996;237-248.
137. Douglass J., Daoud S. Characterization of the human cDNA and genomic DNA encoding CART: a cocaine- and amphetamine-regulated transcript. Gene. 169:1996;241-245.
138. Melikian H.E., Ramamoorthy S., Tate C.G., Blakely R.D. Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition. Mol. Pharmacol. 50:1996;266-276.
139. Hornsby P.P., Wilcox A.J., Herbst A.L. Onset of menopause in women exposed to diethylstilbestrol in utero. Am. J. Obstet. Gynecol. 172:1995;92-95.
140. Hornsby P.P., Wilcox A.J., Weinberg C.R., Herbst A.L. Effects on the menstrual cycle of in utero exposure to diethylstilbestrol. Am. J. Obstet. Gynecol. 170:1994;709-715.
141. Wilcox A.J., Baird D.D., Weinberg C.R., Hornsby P.P., Herbst A.L. Fertility in men exposed prenatally to diethylstilbestrol. N. Engl. J. Med. 332:1995;1411-1416.
142. Adams S.P., Laws G.M., Storer R.D., DeLuca J.G., Nichols W.W. Detection of DNA damage induced by human carcinogens in acellular assays: potential application for determining genotoxic mechanisms. Mutation Res. 368:1996;235-248.
143. Moorthy B., Liehr J., Randerath E., Randerath K. Evidence from 32P-postlabeling and the use of pentachlorophenol for a novel metabolic activation pathway of diethylstilbestrol and its dimethyl ether in mouse live: likely alpha-hydroxylation of ethyl group(s) followed by sulfate conjugation. Carcinogenesis. 16:1995;2643-2648.
144. Gladek A., Liehr J.G. Transplacental genotoxicity of diethylstilbestrol. Carcinogenesis. 12:1991;773-776.
145. Dunkel V.C., Zeiger E., Brusick D., McCoy E., McGregor D., Mortlemans K., Rosenkranz H.S., Simmon V.F. Reproducibility of microbial mutagenicity assays. I. Tests with Salmonella typhimurium and Escherichia coli using a standardized protocol Environ. Mutagen. 6:1984;1-251.
146. Myhr B.C., Caspary W.J. Evaluation of the L5178Y mouse lymphoma cell mutagenesis assay: Intralaboratory results for sixty-three coded chemicals tested at Litton Bionetics, Inc. Environ. Mol. Mutagen. 12:1988;103-194.
147. Dean B.J., Danford N., Douglas G., Gulati D., Ishidate M., Palitti F., Phillips B., Richardson C., Van-Went G. Summary report on the performance of cytogenetic assays in cultured cells. Progr. Mutation Res. 5:1985;69.
148. DeSario A., Vagnarelli P., DeCarli L. Aneuploidy assay on diethylstilbestrol by means of in situ hybridization of radioactive and biotinylated DNA probes on interphase nuclei. Mutation Res. 243:1990;127-131.
149. Eastmond D.A., Pinkel D. Detection of aneuploidy and aneuploidy-inducing agents in human lymphocytes using fluorescence in situ hybridization with chromosome-specific DNA probes. Mutation Res. 234:1990;303-318.
150. Pylkkanen L., Jahnukainen K., Parvinen M., Santti R. Testicular toxicity and mutagenicity of steroidal and non-steroidal estrogens in the male mouse. Mutation Res. 261:1991;181-191.
151. Epe B., Hegler J., Metzler M. Site-specific covalent binding of stilbener-type and steroidal estrogens to tubulin following metabolic activation in vitro. Carcinogenesis. 8:1987;1271-1275.
152. Hartley-Asp B., Deinum J., Wallin M. Diethylstilbesterol induces metaphse arrests and inhibits microtubule assembly. Mutation Res. 143:1985;231-235.
153. J.J. Li, Perspectives in hormonal carcinogenesis: Animal models to human disease, in: J. Huff, J. Boyd, J.C. Barrett (Eds.), Cellular and Molecular Mechanisms of Hormonal Carcinogenesis, Wiley-Liss, New York, 1996.
154. Nelson K.G., Sakai Y., Eitzman B., Steed T., McLachlan J.A. Exposure to diethylstilbestrol during a critical developmental period of the mouse reproductive tract leads to persistent induction of two estrogen-regulated genes. Cell Growth Diff. 5:1994;595-606.
155. Newbold R. Cellular and molecular effects of developmental exposure to diethylstilbestrol: Implications for other environmental estrogens. Environ. Health Perspect. 103:1995;83-87.
156. Newbold R., Hanson R.B., Jefferson W.N. Ontogeny of lactoferrin in the developing mouse uterus: A marker of early hormone response. Biol. Reprod. 56:1997;1147-1157.
157. S. Li, K.A. Washburn, R. Moore, T. Uno, C. Teng, R.R. Newbold, J.A. McLachlan, Developmental exposure to diethylstilbestrol elicits demethylation of estrogen-responsive lactogerrin gene in mouse uterus, Cancer Res., 1997, in press.
158. Musselman A.C., Bennett G.D., Greer K.A., Eberwine J.H., Finnell R.H. Preliminary evidence of phenytoin-induced alterations in embryonic gene expression in a mouse model. Reprod. Toxicol. 8:1994;383-395.
159. Bennett G.D., Lau F., Calvin J.A., Finnell R.H. Phenytoin-induced teratogenesis: a molecular basis for the observed developmental delay during neurulation. Epilepsia. 38:1997;415-423.
160. Brunius G., Yucel-Lindberg T., Shinoda K., Modeer T. Effect of phenytoin on interleukin-1 beta production in human gingival fibroblasts challenged to tumor necrosis factor alpha in vitro. Eur. J. Oral Sci. 104:1996;27-33.
161. Diwan B.A., Henneman J.R., Nims R.W., Rice J.M. Tumor promotion by an anticonvulsant agent, phenytoin, in mouse liver: correlation with CYP2B induction. Carcinogenesis. 14:1993;2227-2231.
162. Volk B., Meyer R.P., vonLintig F., Ibach B., Knoth R. Localization and characterization of cytochrome P450 in the brain. In vivo and in vitro investigations on phenytoin- and phenobarbital-inducible isoforms. Toxicol. Lett. 82(83):1995;655-662.
163. Haworth S., Lawlor T., Mortelmans K., Speck W., Zeiger E. Salmonella mutagenicity test results for 250 chemicals. Environ. Mutagen. 5(suppl. 1):1983;3-142.
164. B. Myhr, L. Bower, W. Caspary, Assays for the induction of gene mutations at the thymine kinase locus in L5178Y mouse lymphoma cells in culture, in: J. Ashby, F. deSerres, M. Draper, M.J. Ishidate, B. Margolin, B. Matter, M. Shelby (Eds.), Evaluation of Short-Term Tests for Carcinogens, Elsevier, Amsterdam, 1985, pp. 555-568.
165. Woodruff R.C., Mason J.M., Valencia R., Zimmering S. Chemical mutagenesis testing in Drosophila. V. Results of 53 coded compounds tested for the National Toxicology Program Environ. Mutagen. 7:1985;677-702.
166. Galloway S., Armstron M., Reuben C., Colman S., Brown B., Cannon C., Bloom A., Nakamura F., Ahmed M., Duk S., Rimpo J., Margolin B., Resnick M., Anderson B., Zeiger E. Chromosome aberration and sister chromatid exchanges in Chinese hamster ovary cells: Evaluations of 108 chemicals. Environ. Mol. Mutagen. 10(suppl. 10):1987;1-176.
167. McFee A.F., Tice R.R., Shelby M.D. In vivo cytogenetic activity of diphenylhydantoin in mice. Mutation Res. 278:1992;61-68.
168. Montes-de-Oca-Luna R., Leal-Garza C.H., Baca-Sevilla S., Garza-Chapa R. The effect of diphenylhydantoin on the frequency of micronuclei in bone marrow polychromatic erythrocytes of mice. Mutation Res. 141:1984;183-187.
169. Barcellona P.S., Barale R., Campana A., Zucconi D., Rossi V., Caranti S. Correlations between embryotoxic and genotoxic effects of phenytoin in mice. Teratol. Carcinog. Mutagen. 7:1987;159-168.
170. Kindig D., Garriott M.L., Parton J.W., Brunny J.D., Beyers J.E. Diphenylhydantoin is not genotoxic in a battery of short-term cytogenetic assays. Terato. Carcinog. Mutagen. 12:1992;43-50.
171. Taneja N., Jain S., Maheswari M.C., Tandon J.K., Kucheria K. Induction of sister chromatid exchanges in phenytoin treated and untreated patients with epilepsy. Indian J. Med. Res. 96:1992;302-305.
172. Slamenova D., Budayova E., Gabelova A., Moravkova A., Panikova L. Results of genotoxicity testing of mazindol (degonan),lithium carbonicum (contemnol) and dropropizine (ditustat) in Chinese hamster V79 and human EUE cells. Mutation Res. 169:1986;171-177.
173. Weiner M.L., Batt K.J., Putman D.L., Curren R.D., Yang L.L. Genotoxicity evaluation of lithium hypochlorite. Toxicology. 65:1990;1-22.
174. Leonard A., Hantson P., Gerber G.B. Mutagenicity, carcinogenicity, and teratogenicity of lithium compounds. Mutation Res. 339:1995;131-137.
175. Driever W. Axis formation in zebrafish. Curr. Opin. Genet. Dev. 5:1995;610-618.
176. Stachel S.E., Grunwald D.J., Myers P.Z. Lithium perturbation and goosecoid expression identify a dorsal specification pathway in the pregastrula zebrafish. Development. 117:1993;1261-1274.
177. Brivanlou A.H., Harland R.M. Expression of an engrailed-related protein is induced in the anterior neural ectoderm of early Xenopus embryos. Development. 106:1989;611-617.
178. Ruiz-i-Altaba A., Melton D.A. Bimodal and graded expression of the Xenopus homeobox gene Xhoux3 during embryonic development. Develop. 106:1989;173-183.
179. Sato S.M., Sargent T.D. Molecular approach to dorsoanterior development in Xenopus laevis. Dev. Biol. 137:1990;135-141.
180. Drysdale T.A., Tonissen K.F., Patterson K.D., Crawford M.J., Krieg P.A. Cardiac troponin I is a heart-specific marker in the Xenopus embryo: expression during abnormal heart morphogenesis. Dev. Biol. 165:1994;432-441.
181. Wang J.M., Lin-Shiau S.Y., Lin J.K. Relaxation of rat thoracic aorta by N-nitroso compounds and nitroprusside and their modifications of nucleic acid bases through release of nitric oxide. Biochem. Pharmacol. 45:1993;819-825.
182. Epe B., Hegler J., Wild D. Singlet oxygen as an ultimately reactive species in Salmonella typhimurium DNA damage induced by methylene blue/visible light. Carcinogenesis. 10:1989;2019-2024.
183. McBride T.J., Schneider J.E., Floyd R.A., Loeb L.A. Mutations induced by methylene blue plus light in single-stranded M13mp2. Proc. Natl. Acad. Sci. USA. 89:1992;6866-6870.
184. Tudek B., Laval J., Boiteux S. SOS-independent mutagenesis in lacZ induced by methylene blue plus visible light. Mol. Gen. Genet. 236:1993;433-439.
185. Chung, Fulk, Andrews Mutagenicity testing of some commonly used dyes. Appl. Environ. Microbiol. 42:1981;641-648.
186. Gutter B., Speck W.T., Rosenkranz H.S. A study of the photoinduced mutagenicity of methylene blue. Mutation Res. 44:1977;177-182.
187. Lunn A.A., Sansone A.A. Decontamination of aqueous solutions of biological stains. Biotech. Histochem. 66:1991;307-315.
188. Wagner S.J., Cifone M.A., Murli H., Dodd R.Y., Myhr B. Mammalian genotoxicity assessment of methylene blue in plasma: implications for virus inactivation. Transfusion. 35:1995;407-413.
189. Mortelmans K., Haworth S., Lawlor T., Speck W., Tainer B., Zeiger E. Salmonella mutagenicity tests. II. Results from the testing of 270 chemicals Environ. Mutagen. 8(suppl 7):1986;1-119.
190. NTP, Technical Report 476, Toxicology and Carcinogenesis Studies of Primidone in F344/N Rats and B6C3F1 Mice, U.S. Department of Health and Human Services, PHS, NIH, Peer Reviewed December 11-12, 1996.
191. Zolotareva G.N., Akaeva E.A., Goncharova R.I. Antimutagenic activity of the antispasmodic preparation hexamidine. Effect of hexamide on the level of spontaneous mutation in a number of subjects. Dokl. Acad. Nauk. 246:1979;469-471.
192. Riedel L., Obe G. Mutagenicity of antiepileptic drugs. II. Phenytoin, primidone and phenobarbital Mutation Res. 138:1984;71-74.
193. Stenchever M.A., Allen M. The effect of selected antiepileptic drugs on the chromosomes of human lymphocytes in vitro. Am. J. Obstet. Gynecol. 116:1973;867-870.
194. Bishun N.P., Smith N.S., Williams D.C. Chromosomes and anticonvulsant drugs. Mutation Res. 28:1975;141-143.
195. Epstein S.S., Arnold E., Andrea J., Bass W., Bishop Y. Detection of chemical mutagens by the dominant lethal assay in the mouse. Tox. Appl. Pharm. 23:1972;288-325.
196. Rao K.P., Shaheen S., Usha-Rani M.V., Rao M.S. Effect of primidone in somatic and germ cells of mice. Toxicol. Lett. 34:1986;149-152.
197. E. Zeiger, S. Haworth, Tests with a preincubation modification of the Salmonella/microsome assay, in: J. Ashby, F. deSerres, M. Draper, M.J. Ishidate, B. Margolin, B. Matter, M. Shelby (Eds.), Evaluation of Short-Term Test for Carcinogens, Elsevier, New York, 1985, pp. 187-199.
198. E. Gulati, P. Sabharwal, M. Shelby, Tests for the induction of chromosomal aberrations and sister chromatid exchanges in cultured Chinese hamster ovary (CHO) cells, in: J. Ashby, F. deSerres, M. Draper, M.J. Ishidate, B. Margolin, M. Shelby (Eds.), Evaluation of Short-Term Tests for Carcinogens, Elsevier, New York, 1985, pp. 413-426.
199. Stenchever M.A., Jarvis J.A. Diphenyldhydantion: Effects on the chromosomes of human leukocytes. Am. J. Obstet. Gynecol. 109:1971;961-962.
200. Devaki-Nandan S., Sanjeeva-Rao M. Evaluation of the mutagenic effects of phenobarbital by dominant lethal assay in Swiss mice. Food Chem. Toxicol. 21:1983;335-337.
201. Whyener J., Ross P.M., Williams G.M. Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol. Ther. 71:1996;153-191.
202. Lechner M.C., Ribeiro V.L., Henrique D., Barroso M., Cravino M.M. Modulation of mRNAs P450 and hepatocarcinogenesis promotion. Bull. Cancer Paris. 77:1990;509-514.
203. Fournier T., Vranckx R., Mejdoubi N., Durand G., Porquet D. Induction of rat alpha-1 acid glycoprotein by phenobarbital is independent of a general acute-phase response. Biochem. Pharmacol. 48:1994;1531-1535.
204. Stroop C.J., Dutmer A.A., Horbach G.J. Changes in chromatin structure and nuclear matrix association of the rat cytochrome P450 2B1/2 (CYP2B1/2) gene following induction with phenobarbital. J. Biochem. Toxicol. 11:1996;59-65.
205. Brun A., Cuany A., LeMouel T., Berge J., Amichot M. Inducibility of the Drosophila melanogaster cytochrome P450 gene, CYP6A2, by phenobarbital in insecticide susceptible or resistant strains. Insect Biochem. Mol. Biol. 26:1996;697-703.
206. Brierley C.H., Senafi S.B., Clarke D., Hsu M.H., Johnson E.F., Burchell B. Regulation of the human bilirubin UDP-glucuronosyltransferase gene. Adv. Enzyme Regul. 36:1996;85-97.
207. Qin S., Huang C.C. Effect of retinoids on carcinogen-induced mutagenesis in Salmonella tester strains. Mutation Res. 142:1985;115-120.
208. Okai Y., Higashi-Okai K., Nakamura S., Yano Y., Otani S. Suppressive effects of retinoids, carotenoids and antioxidant vitamins on heterocyclic amine-induced umu C gene expression in Salmonella typhimurium (TA 1535/pSK 1002). Mutation Res. 368:1996;133-140.
209. Rutledge J.C., Shourbaji A.G., Hughes L.A., Polifka J.E., Cruz Y.P., Bishop J.B., Generoso W.M. Limb and lower-body duplications induced by retinoic acid in mice. Proc. Natl. Acad. Sci. USA. 91:1994;5436-5440.
210. Eichele G. Retinoids and vertebrate limb pattern formation. Trends Genet. 5:1989;246-251.
211. Francis-West P.H., Robertson K.E., Ede D.A., Rodreguez C., Izpisua-Belmonte J.C., Houston B., Burt D.W., Gribbin C., Brickell P.M., Tickle C. Expression of genes encoding bone morphogenetic proteins and sonic hedgehog in talpid (ta3) limb buds: their relationships in the signalling cascade involved in limb patterning. Dev. Dyn. 203:1995;187-197.
212. Sundin O., Eichele G. An early marker of axial pattern in the chick embryo and its respecification by retinoic acid. Development. 114:1992;841-852.
213. Ang H.L., Deltour L., Hayamizu T.F., Zgombic-Knight M., Duester G. Retinoic acid synthesis in mouse embryos during gastrulation and craniofacial development linked to class IV alcohol dehydrogenase gene expression. J. Biol. Chem. 271:1996;9526-9534.
214. Cunningham M.L., MacAuley A., Mirkes P.E. From gastrulation to neuralation: transition in retinoic acid sensitivity identifies distinct stages of neural patterning in the rat. Dev. Dyn. 200:1994;227-241.
215. Donovan M., Olofsson B., Gustafson A.L., Dencker L., Eriksson U. The cellular retinoic acid binding proteins. J. Steroid Biochem. Mol. Biol. 53:1995;459-465.
216. Sucov H.M., Izpisua-Belmonte J.C., Ganan Y., Evans R.M. Mouse embryos lacking RXR alpha are resistant to retinoic-acid-induced limb defects. Development. 121:1995;3997-4003.
217. Venepally P., Reddy L.G., Sani B.P. Analysis of the effects of CRABP-I expression on the RA-induced transcription mediated by retinoid receptors. Biochemistry. 35:1996;9974-9982.
218. Schindler R., Dinarello C.A., Koch K.M. Angiotensin-converting-enzyme inhibitors suppress synthesis of tumor necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine. 7:1995;526-533.
219. Ohta K., Kim S., Hamaguchi A., Miura K., Yukimura T., Iwao H. Cardiac hypertrophy-related gene expression in spontaneously hypertensive rats: crucial role of antiotensin. Jpn. J. Pharmacol. 65:1995;95-99.
220. alHarbi M.M. Effect of captopril on the cytological and biochemical changes induced by adriamycin. Food Chem. Toxicol. 31:1993;209-212.
221. Castren K., Pienimaki P., Arvela P., Vahakangas K. Metabolites and DNA-binding of carbamazepine and oxcarbazepine in vitro by rat liver microsomes. Hum. Exp. Toxicol. 15:1996;577-582.
222. Sinues B., Gazulla J., Bernal M.L., Lanuza J., Fanlo A., Saenz M.A., Barolome M. Six mutagenicity assays in exposure biomonitoring of patients receiving carbamazepine for epilepsy or trigeminal neuralgia. Mutation Res. 334:1995;259-265.
223. Schaumann B., Satish J., Johnson S.B., Moore K., Cervenka J. Effects of carbamazepine on human chromosomes. Epilepsia. 26:1985;346-352.
224. Glatt H.R., Oesch F., Frigerio A., Garattini S. Epoxides metabolically produced from some known carcinogens and from some clinically used drugs I. Differences in mutagenicity. Int. J. Cancer. 16:1975;787-797.
225. Grigg G.W. Genetic effects of coumarins. Mutation Res. 47:1978;161-181.
226. Norman R.L., Wood A.W. Assessment of the mutagenic potential of coumarin in histidine-dependent strains of Salmonella typhimurium. Am. Soc. Clin. Oncol. 22:1981;109.
227. Stoltz D.R., Scott P.M. Mutagenicity of coumarin and related compounds for Salmonella typhimurium. Can. J. Genet. Cytol. 22:1980;679.
228. Valencia R., Mason J.M., Zimmering S. Chemical mutagenesis testing in Drosophila VI. Interlaboratory comparison of mutagenicity tests after treatment of larvae. Environ. Mol. Mutagen. 14:1989;238-244.
229. Yoon J.S., Mason J.M., Valencia R., Woodruff R.C., Zimmering S. Chemical mutagenesis testing in Drosophila. 4. Results of 45 coded compounds tested for the National Toxicology Program Environ. Mutagen. 7:1985;349-367.
230. Aiyar J., DeFlora S., Wetterhahn K.E. Reduction of chromium (VI) to chromium (V) by rat liver cytosolic and microsomal fractions: is DT-diaphorase involved? Carcinogenesis. 13:1992;1159-1166.
231. DeFlora S., Bennicelli C., D'Agostini F., Izzotti A., Camoirano A. Cytosolic activation of aromatic and heterocyclic amines. Inhibition by dicoumarol and enhancement in viral hepatitis B. Environ. Health Perspect. 102(suppl. 6):1994;69-74.
232. Hasspieler B.M., Haffner G.D., Adeli K. Influence of DT diaphorase on quinone-mediated genotoxicity in human and fish cell lines. Mutation Res. 360:1996;43-49.
233. Smiskamp-Wilms E., Peters G.J., Pinedo H.M., van Ark-Otte J., Giaccone G. Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. Biochem. Pharmacol. 47:1994;1325-1332.
234. Lee M.T., Kaushansky K., Ralph P., Ladner M.B. Differential expression of M-CSF, G-CSF, and GM-CSF by human monocytes. J. Leukocyte Biol. 47:1990;275-282.
235. Patil R.R., Borch R.F. Granulocyte-macrophage colony-stimulating factor expression by human fibroblasts is both upregulated and subsequently downregulated by interleukin-1. Blood. 85:1995;80-86.
236. Temime N., Joliviere A., Lando D., Teyton L., Charron D. Autocrine stimulation of interleukin 1 in human adherent synovial lining cells: down regulation by interferon gamma. Hum. Immunol. 31:1991;261-270.
237. Devi P.S., Polasa H. Evaluation of the anti-inflammatory drug indomethacin, for its genotoxicity in mice. Mutation Res. 188:1987;343-347.
238. Abe S. Effects of arachidonic acid and indomethacin on sister-chromatid exchange induction by polycyclic aromatic hydrocarbons in mammalian cell lines. Mutation Res. 173:1986;55-60.
239. Guthrie J., Robertson I.G., Zeiger E., Boyd J.A., Eling T.E. Selective activation of some dihydrodiols of several polycyclic aromatic hydrocarbons to mutagenic products by prostaglandin synthetase. Cancer Res. 42:1982;1620-1623.
240. Lee S.H., Norppa H. Effects of indomethacin and arachidonic acid on sister chromatid exchange induction by styrene and styrene-7,8-oxide. Mutation Res. 348:1995;175-181.
241. Chong Y.C., Heppner G.H., Paul L.A., Fulton A.M. Macrophage-mediated induction of DNA strand breaks in target tumor cells. Cancer Res. 49:1989;6652-6657.
242. Obrecht-Pflumio S., Grosse Y., Pfohl-Lexzkowicz A., Dirheimer G. Protection by indomethacin and aspirin against genotoxicity of ochratoxin A, particularly in the urinary bladder and kidney. Arch. Toxicol. 70:1996;244-248.
243. Pirozzi S.J., Renz J.F., Kalf G.F. The prevention of benzene-induced genotoxicity in mice by indomethacin. Mutation Res. 222:1989;291-298.
244. Hashimoto T., Takeuchi K., Ohno S., Komatsu S. Mutagenicity tests of the antithyroid agent thiamazole. Cytogenetic studies on male mice. J. Toxicol. Sci. 12:1987;23-32. published erratum in J. Toxicol. Sci., 12, 164.
245. Akatsuka K., Hashimoto T., Takeuchi K., Ohhira M. Mutagenicity test of antithyroid agent, methimazole - dominant lethal mutation test on male mice. J. Toxicol. Sci. 4:1979;127-137.
246. Novotna B., Duverger-vanBogaert M. Role of kidney S9 in the mutagenic properties of 1,2-dibromoethan. Toxicol. Lett. 74:1994;255-263.
247. Wagner E.D., Verdier M.M., Plewa M.J. The biochemical mechanism of the plant activation of promutagenic aromatic amines. Environ. Mol. Mutagen. 15:1990;236-244.
248. Wagner E.D., Gentile J.M., Plewa M.J. Effects of specific monooxygenase and oxidase inhibitors on the activation of 2-aminofluorene by plant cells. Mutation Res. 216:1989;163-178.
249. Mynatt R.L., Park E.A., Thornagate F.E., Das H.K., Cook G.A. Changes in carnitine palmitoyltransferase I mRNA abundance produced by hyperthyroidism and hypothyroidism parallel changes in activity. Biochem. Biophys. Res. Commun. 201:1994;932-937.
250. Silva J.E., Rudas P. Effects of congenital hypothyroidism on microtubule-associated protein-2 expression in the cerebellum of the rat. Endocrinology. 126:1990;1276-1282.
251. Takeuchi H., Nakagawa Y., Igarashi Y. Studies on gene expression in calvaria and serum levels of insulin-like growth factor-I and bone Gla protein in the methimazole-induced congenital hypothyroid rat. Endocr. J. 40:1993;351-362.
252. Wagner J.P., Seidler F.J., Lappi S.E., McCook E.C., Slotkin T.A. Role of thyroid status in the ontogeny of adrenergic cell signalling in rat brain: beta receptors, adenylate cyclase, ornithine decarboxylase and c-fos protooncogene expression. J. Pharmacol. Exp. Ther. 271:1994;472-483.
253. C. Ramel, Genetic effects, in: L. Friberg, D. Vostal (Eds.), Mercury in the Environment: Toxicological Effects and Epidemiological and Toxicological Appraisal, CRC Press, Cleveland, 1972, pp. 169-181.
254. Leonard A., Jacquet P., Lauwerys R.R. Mutagenicity and teratogenicity of mercury compounds. Mutation Res. 114:1983;1-18.
255. Valencia R., Mason J.M., Woodruff R.C., Zimmering S. Chemical mutagenesis testing in Drosophila III. Results of 48 coded compounds tested for the National Toxicology Program. Environ. Mutagen. 7:1985;325-348.
256. Mathew C., Al-Doori Z. The mutagenic effect of the mercury fungicide Ceresan M in Drosophila melanogaster. Mutation Res. 40:1976;31-36.
257. Hofer B., Eltis L.D., Dowling D.N., Timmis K.N. Genetic analysis of a Pseudomonas locus encoding a pathway for biphenyl/polychlorinated biphenyl degredation. Gene. 130:1993;47-55.
258. Khan A.A., Walia S.K. Expression, localization and functional analysis of polychlorinated biphenyl degredation genes cbpABCD of Pseudomonas putida. Appl. Environ. Microbiol. 54:1991;1325-1332.
259. Nordlund-Moller L., Anderson O., Ahlgren R., Schilling H., Gillner M., Gustafsson J.A., Lund J. Cloning, structure, and expression of a rat binding protein for polychlorinated biphenyls. Homology to the hormonally regulated progesterone-binding protein uteroglobin. J. Biol. Chem. 265:1990;12690-12693.
260. Dragnev K.H., Nims R.W., Fox S.D., Lindahl R., Lubet R.A. Relative potencies of induction of hepatic drug-metabolizing enzyme genes by individual PCB congeners. Toxicol. Appl. Pharmacol. 132:1995;334-342.
261. Safe S. Polychlorinated biphenyls (PCBs): mutagenicity and carcinogenicity. Mutation Res. 220:1989;31-47.
262. Belpaeme K., Delbeke K., Zhu L., Kirsch-Volders M. PCBs do not induce DNA breakage in vitro in human lymphocytes. Mutagenesis. 11:1996;485-492.
263. Hsai M.T., Lin F.S., Allen J.R. Comparative mutagenicity and toxic effects of 2,5,2′,5′-tetrachlorobiphenyl and its metabolites in bacterial and mammalian test systems. Res. Commun. Chem. Pathol. Pharmacol. 21:1978;485-496.
264. Schoeny R.S. Non-mutagenicity for Salmonella of the hydrocarbons aroclor 1254, 1,2,4-trichlorobenzene, mirex, and kepone. Mutation Res. 68:1979;125-132.
265. Schoeny R. Mutagenicity testing of chlorinated biphenyls and chlorinated dibenzofurans. Mutation Res. 101:1982;45-56.
266. Sargent L., Roloff B., Meisner L. In vitro chromosome damage due to PCB interactions. Mutation Res. 224:1989;79-88.
267. Balpaeme K., Delbeke K., Zhu L., Kirsch-Volders M. Cytogenetic studies of PCB77 on brown trout (Salmo trutta fario) using the micronucleus test and the alkaline comet assay. Mutagenesis. 11:1996;485-492.
268. Nagayama J., Nagayama M., Haraguchi K., Kuroki H., Masuda Y. Influence of five methylsulphonyl PCB congeners on frequency of micronucleated cells in cultured human lymphocytes by cytokinesis block method. Fukuoka, Igaku Zasshi. 36:1995;190-196.
269. Sideropoulos A.S., Specht S.M., Jones M.T. Feasibility of testing DNA repair inhibitors for mutagenicity by a simple method. Mutation Res. 74:1980;95-105.
270. King M.T., Beikirch H., Eckhardt K., Gocke E., Wild D. Mutagenicity studies with X-ray-contrast media, analgesics, antipyretics, antirheumatics and some other pharmaceutical drugs in bacterial, Drosophila and mammalian test systems. Mutation Res. 66:1979;33-43.
271. Munzner R., Renner H.W. Mutagenicity testing of quinine with submammalian and mammalian systems. Toxicology. 26:1983;173-178.
272. Anderson B.E., Zeiger E., Shelby M.D., Resnick M.A., Gulati D.K., Ivett J.L., Loveday K.S. Chromosome aberration and sister chromatid exchange test results with 42 chemicals. Environ. Mol. Mutagen. 16(suppl. 18):1990;55-137.
273. Myhr B.C., McGregor D., Bowers L., Riach C., Brown A., Edwards I., McBride D., Martin R., Caspary W.J. L5178Y mouse lymphoma cell mutation assay results with 41 compounds. Environ. Mol. Mutagen. 16(suppl. 18):1990;138-167.
274. Andrews A.W., Fornwald J.A., Lijinsky W. Nitrosation and mutagenicity of some amine drugs. Toxicol. Appl. Pharmacol. 52:1980;237-244.
275. McGregor D.B., Brown A.G., Howgate S., McBride D., Riach C., Caspary W. Responses of the L5178Y mouse lymphoma cell forward mutation assay. V: 27 coded chemicals Environ. Mol. Mutagen. 17:1991;196-219.
276. Blitek D., Pienkowska K., Gajcy H., Koziorowska J. Mutagenicity of oxytetracyline. Mutation Res. 117:1983;193-199.
277. Ackland-Berglund C.E., Leib D.A. Efficacy of tetracycline-controlled gene expression is influenced by cell type. Biotechniques. 18:1995;196-200.
278. Hennighausen L., Wall R.J., Tillmann U., Li M., Furth P.A. Conditional gene expression in secretory tissues and skin of transgenic mice using the MMTV-LTR and the tetracycline responsive system. J. Cell Biochem. 59:1995;463-472.
279. Liang X., Hartikka J., Sukhu L., Manthorpe M., Hobart P. Novel, high expressing and antibiotic-controlled plasmid vectors designed for use in gene therapy. Gene Ther. 3:1996;350-356.
280. O'Brien K., Otto K., Rao R.N. Construction and characterization of a one-plasmid system for the controlled expression of genes in mammalian cells by tetracycline. Gene. 184:1997;115-120.
281. Pescini R., Alouani S., Proudfoot A., Power C., Mermod J.J., DeLamarter J.F., Hooft-vanHuijsduijnen R. Inducible inhibition of eukaryotic gene expression. Biochem. Biophys. Res. Commun. 202:1994;1664-1667.
282. J. Ashby, H. Tinwell, R.D. Callander, I. Kimber, P. Clay, S.M. Galloway, R.B. Hill, S.K. Greenwood, M.E. Gaulden, E. Vogel, M. Nivard, J.M. Parry, J. Williamson, Thalidomide: lack of mutagenic activity across phyla and genetic endpoints, Mutation Res., this issue.
283. Gordon G.B., Spielberg S.P., Blake D.A., Balasubramanian V. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc. Natl. Acad. Sci. USA. 78:1981;2545-2548.
284. Soukup S., Takacs E., Warkny J. Chromosome changes in embryos treated with various teratogens. J. Embryol. Exp. Morphol. 18:1967;215-226.
285. Roux C., Emerit I., Tailemite J.L. Chromosomal breakage and teratogenesis. Teratology. 4:1971;303-316.
286. McBride W.G. Thalidomide may be a mutagen. Br. Med. J. 308:1994;1635-1636.
287. Tenconi R., Clementi M., Notari L., Lovasco V.R. Amniotic band sequence in child of thalidomide victim. Br. Med. J. 309:1994;1442.
288. Kida M. Thalidomide may not be a mutagen. Br. Med. J. 309:1994;741.
289. Read A.P. Thalidomide may be a mutagen. Comp. Biochem. Physiol. 308:1994;1636.
290. Ashby J., Tindall H. Is thalidomide mutagenic? Nature. 375:1995;453.
291. Wilkins-Haug L. Teratogen update: Toluene. Teratology. 55:1997;145-151.
292. Fishbein L. Genetic effects of benzene, toluene and xylene. IARC Sci. Publ. 85:1988;19-46.
293. McGregor D. The genetic toxicology of toluene. Mutation Res. 317:1994;213-228.
294. NTP, Toxicology and Carcinogenesis Studies of Toluene in F344/N Rats and B6C3F1 Mice, 1990.
295. McGregor D.B., Brown A., Cattanach P., Edwards I., McBride D., Riach C., Caspary W.J. Responses of the L5178Y tk+/tk- mouse lymphoma cell forward mutation assay. III. 72 coded chemicals Environ. Mol. Mutagen. 12:1988;85-154.
296. Richer C.L., Chakrabarti S., Senecal-Quevillon M., Duhr M.A., Zhang X.X., Tardif R. Cytogenetic effects of low-level exposure to toluene, xylene, and their mixture on human blood lymphocytes. Int. Arch. Occup. Environ. Health. 64:1993;581-585.
297. Pitarque M., Carbonell E., Lapena N., Marsa M., Torres M., Creus A., Xamena N., Marcos R. No increase in micronuclei frequency in cultured blood lymphocytes from a group of filling station attendants. Mutation Res. 367:1996;161-167.
298. Feldman G.L., Weaver D.D., Lovrien E.W. The fetal trimethadione syndrome: report of an additional family and further delineation of this syndrome. Am. J. Dis. Child. 131:1977;1389-1392.
299. Hu L.J., Lu X.F., Lu B.Q., Huang Y.Q. The effect of valproic acid on SCE and chromosome aberrations in epileptic children. Mutation Res. 243:1990;63-66.
300. Schaumann B.A., Winge V.B., Garry V.F. Sister chromatid exchanges in adult epilepsy patients on valproate monotherapy. Epilepsy Res. 3:1989;182-184.
301. Taneja N., Kucheria K., Jain S., Tandon J.K., Maheshwari M.C. Sister chromatid exchanges are increased in epileptics, but not by sodium valproate. Mutation Res. 283:1992;233-235.
302. K.K. Terry, S.L. Dial, R.D. Streck, D.K. Hansen, Valproic acid exposure and the expression of neural cell adhesion molecules during mouse neural tube closure, 37th Annual Meeting of the Teratology Society, 1997, Abstract-75.
303. Nebert Drug metabolism and signal transduction: possible role of Ah receptor and arachidonic acid cascade in protection from ethanol toxicity. EXS. 71:1994;231-240.